VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock.

A number of other research analysts also recently weighed in on the company. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $2.50 price objective on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Price Performance

VNRX opened at $0.72 on Friday. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.38. The business has a 50-day moving average of $0.64 and a 200-day moving average of $0.75. The company has a market capitalization of $66.31 million, a PE ratio of -1.57 and a beta of 1.13.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.34 million. On average, equities research analysts expect that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Transactions at VolitionRx

In other news, Director Guy Archibald Innes acquired 150,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the acquisition, the director now owns 406,683 shares of the company’s stock, valued at $272,477.61. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.80% of the stock is owned by insiders.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.